Glioblastoma (GBM) is the most common primary malignant brain tumor in adults and has an
exceedingly low median overall survival of only 15 months. Current standard-of-care for …

Patients with glioblastoma (GBM) have a universally poor prognosis and are in urgent need
of effective treatment strategies. Recent advances in sequencing techniques unraveled the …

Activated EGFR signalling drives tumorigenicity in 50% of glioblastoma (GBM). However,
EGFR-targeting therapy has proven ineffective in treating patients with GBM, indicating that …

Chimeric antigen receptor (CAR)-T-cell therapy for solid tumors is limited due to
heterogeneous target antigen expression and outgrowth of tumors lacking the antigen …

Cancer diagnosis, prognosis, mymargin and therapeutic response predictions are based on
morphological information from histology slides and molecular profiles from genomic data …

Nowadays, due to recent advances in molecular biology, the pathogenesis of glioblastoma
is better understood. For the newly diagnosed, the current standard of care is represented by …

Over the past century, treatment of malignant tumors of the brain has remained a challenge.
Refinements in neurosurgical techniques, discovery of powerful chemotherapeutic agents …

Glioblastoma (GBM) is a lethal brain tumor containing a subpopulation of glioma stem cells
(GSC). Pan-cancer analyses have revealed that stemness of cancer cells correlates …

Translation of novel therapies for brain cancer into clinical practice is of the utmost
importance as primary brain tumors are responsible for more than 200,000 deaths …

Background: Glioblastoma (GBM) is a highly aggressive cancer with poor prognosis that
needs better treatment modalities. Moreover, there is a lack of reliable biomarkers to predict …